Last $9.00 USD
Change Today -0.39 / -4.15%
Volume 113.6K
GNMK On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 10/17/14 All times are local (Market data is delayed by at least 15 minutes).

genmark diagnostics inc (GNMK) Snapshot

Open
$9.53
Previous Close
$9.39
Day High
$9.53
Day Low
$8.97
52 Week High
01/16/14 - $14.18
52 Week Low
05/21/14 - $8.48
Market Cap
375.6M
Average Volume 10 Days
136.6K
EPS TTM
$-1.02
Shares Outstanding
41.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GENMARK DIAGNOSTICS INC (GNMK)

Related News

No related news articles were found.

genmark diagnostics inc (GNMK) Related Businessweek News

No Related Businessweek News Found

genmark diagnostics inc (GNMK) Details

GenMark Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, sells, and supports instruments and molecular tests based on its proprietary eSensor detection technology in the United States. The company’s products include XT-8 system, an automated molecular diagnostic system that enables reference laboratories and hospitals to perform molecular diagnostic tests. It also offers 8 diagnostic tests for use with its XT-8 system that includes Cystic Fibrosis Genotyping Test, which detects a panel of mutations associated with cystic fibrosis; Warfarin Sensitivity test that determines an individual’s ability to metabolize the oral anticoagulant warfarin; Thrombophilia Risk Test, which detects an individual’s increased risk of blood clots; and Respiratory Viral Panel test that simultaneously detects and differentiates 14 clinically relevant viruses from patients with influenza-like illnesses. The company’s diagnostic tests also include Hepatitis C Virus Genotyping test for the detection and typing/subtyping of HCV; 3A4/3A5 Genotyping test designed for the detection and genotyping of the alleles of the CYP450 3A4 gene locus and CYP450 3A5 gene locus; and 2C19 Genotyping test for the detection and genotyping alleles of the cytochrome P450 (CYP450) 2C19 gene locus. In addition, the company is engaged in developing a NexGen system to integrate automated nucleic acid extraction and amplification with its eSensor detection technology to enable technicians to place a patient sample into test cartridge and obtain results without any additional steps. Genmark Diagnostics, Inc. is headquartered in Carlsbad, California.

153 Employees
Last Reported Date: 03/11/14

genmark diagnostics inc (GNMK) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $450.0K
Senior Vice President of North American Comme...
Total Annual Compensation: $226.2K
Senior Vice President of International
Total Annual Compensation: $154.8K
Senior Vice President of Human Resources
Total Annual Compensation: $248.1K
Compensation as of Fiscal Year 2013.

genmark diagnostics inc (GNMK) Key Developments

GenMark Diagnostics, Inc. Announces Executive Changes

GenMark Diagnostics, Inc. announced the appointment of Dr. James Fox as Chairman of the Board. Dr. Fox is replacing Christopher Gleeson, who is retiring from the Board to attend to personal health matters. Dr. Fox has served on the company's Board since September 2010. Dr. Fox led the start-up of Invetech.

Genmark Diagnostics, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for 2014

GenMark Diagnostics, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported loss from operations of $11,265,000, loss before income taxes was $11,191,000, net loss of $11,210,000 or $0.27 loss per share on total revenue of $6,555,000 against loss from operations of $8,087,000, loss before income taxes was $8,018,000, net loss of $8,019,000 or $0.25 loss per share on total revenue of $5,215,000 for the same period a year ago. For the six months, the company reported loss from operations of $20,124,000, loss before income taxes was $19,967,000, net loss of $19,993,000 or $0.49 loss per share on total revenue of $14,468,000 against loss from operations of $12,318,000, loss before income taxes was $12,186,000, net loss of $12,194,000 or $0.38 loss per share on total revenue of $16,316,000 for the same period a year ago. Net cash used in operating activities was $13,519,000 against $13,328,000 for the same period a year ago. The company also increased its full year 2014 guidance. Total year revenue and gross margin are expected to be approximately $28.0 million and approximately 50%, respectively.

GenMark Diagnostics, Inc. Provides Revenue Guidance for the Second Quarter of 2014

GenMark Diagnostics, Inc. provided revenue guidance for the second quarter of 2014. For the quarter, the company expects of $6.6 million, an increase of 71% over the prior year period.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GNMK:US $9.00 USD -0.39

GNMK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cepheid $46.45 USD +1.78
Luminex Corp $19.32 USD +0.07
Nanosphere Inc $0.73 USD -0.0324
QIAGEN NV €17.22 EUR +0.52
Sequenom Inc $3.21 USD -0.10
View Industry Companies
 

Industry Analysis

GNMK

Industry Average

Valuation GNMK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.5x
Price/Book 4.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENMARK DIAGNOSTICS INC, please visit www.genmarkdx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.